	US 12,421,311 B2
	Anti-CTLA-4 binding proteins and methods of use thereof
David Scott Johnson, San Francisco, CA (US); Adam Shultz Adler, Belmont, CA (US); Rena Aviva Mizrahi, Pacifica, CA (US); Yoong Wearn Lim, Pacifica, CA (US); Michael Asensio, Mountain View, CA (US); and Erica Lyn Stone, San Bruno, CA (US)
Assigned to GigaGen, Inc., San Carlos, CA (US)
Appl. No. 17/418,776
Filed by GigaGen, Inc., San Carlos, CA (US)
PCT Filed Dec. 27, 2019, PCT No. PCT/US2019/068820 § 371(c)(1), (2) Date Jun. 25, 2021, PCT Pub. No. WO2020/140084, PCT Pub. Date Jul. 2, 2020.
Claims priority of provisional application 62/785,659, filed on Dec. 27, 2018.
Prior Publication US 2022/0064303 A1, Mar. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

14 Claims

1. An isolated antigen binding protein (ABP) that specifically binds a human cytotoxic T-lymphocyte associated protein 4 (CTLA-4), comprising a CDR1-L, a CDR2-L, a CDR3-L, a CDR1-H, a CDR2-H and a CDR3-H, wherein:

the CDR1-L consists of SEQ ID NO: 1014,

the CDR2-L consists of SEQ ID NO: 2014,

the CDR3-L consists of SEQ ID NO: 3014,

the CDR1-H consists of SEQ ID NO: 4014,

the CDR2-H consists of SEQ ID NO: 5014 and

the CDR3-H consists of SEQ ID NO: 6014.